Developing tissue specific antisense oligonucleotide-delivery to refine treatment for Duchenne muscular dystrophy

Jirka, S. (2017)

Doctoral Thesis

Duchenne muscular dystrophy (DMD) is a severe progressive muscle wasting disorder. DMD is caused by reading frame disrupting mutations in the DMD gene resulting is an absence of the dystrophin protein. Dystrophin is an important muscle protein as it provide stability upon muscle fiber contraction. Currently there is no therapy for the majority of the DMD patients. As part of the standard of care patient receive symptomatic treatment e.g. corticosteroids, respiratory and cardiac support. Various therapeutic approached are currently under development. Most advanced therapeutic approach is aimed to restore dystrophin production by using antisense oligonucleotides (AON): exon skipping. This thesis focusses on delivery of AON to skeletal and cardiac muscle for DMD. With the help of phage display technology combined with next generation sequencing analyses, muscle homing peptides have been identified. In this thesis is described how for the first time these homing peptides upon conjugation to a 2OMePS AON resulted in increased delivery and exon skipping in a mouse model for DMD. In Conclusion, muscle homing peptides have the potential to facilitate delivery of AONs and perhaps other compounds to skeletal and cardiac muscle.

 

• DMD
• AON
• Phagedisplay
• Peptide
• Next generation sequencing
• Exon skipping
• Muscle

• All authors: Jirka, S.
• Supervisor: Ommen, G.J.B. van; Aartsma-Rus, A.
• Co-supervisor: Hoen, P.H.A. ‘t
• Committee: Goumans, M.; Gait, M.; Kuiper, J.
• Qualification: Doctor (dr.)
• Awarding Institution: Medicine, Leiden University
• Date: 2017-07-04
• ISBN (print): 9789461828088
• Sponsorship: Prinses Beatrix Spierfonds